Search

Your search keyword '"Kambouchner M"' showing total 267 results
Start Over Author "Kambouchner M"
267 results on '"Kambouchner M"'

1. Recommandations pratiques pour le diagnostic et la prise en charge de la fibrose pulmonaire idiopathique – Actualisation 2021. Version intégrale

Author

Cottin, V., Bonniaud, P., Cadranel, J., Crestani, B., Jouneau, S., Marchand-Adam, S., Nunes, H., Wémeau-Stervinou, L., Bergot, E., Blanchard, E., Borie, R., Bourdin, A., Chenivesse, C., Clément, A., Gomez, E., Gondouin, A., Hirschi, S., Lebargy, F., Marquette, C.-H., Montani, D., Prévot, G., Quetant, S., Reynaud-Gaubert, M., Salaun, M., Sanchez, O., Trumbic, B., Berkani, K., Brillet, P.-Y., Campana, M., Chalabreysse, L., Chatté, G., Debieuvre, D., Ferretti, G., Fourrier, J.-M., Just, N., Kambouchner, M., Legrand, B., Le Guillou, F., Lhuillier, J.-P., Mehdaoui, A., Naccache, J.-M., Paganon, C., Rémy-Jardin, M., Si-Mohamed, S., and Terrioux, P.

Published
2022
Full Text
View/download PDF

2. Recommandations pratiques pour le diagnostic et la prise en charge de la fibrose pulmonaire idiopathique – Actualisation 2021. Version courte

Author

Cottin, V., Bonniaud, P., Cadranel, J., Crestani, B., Jouneau, S., Marchand-Adam, S., Nunes, H., Wémeau-Stervinou, L., Bergot, E., Blanchard, E., Borie, R., Bourdin, A., Chenivesse, C., Clément, A., Gomez, E., Gondouin, A., Hirschi, S., Lebargy, F., Marquette, C.-H., Montani, D., Prévot, G., Quetant, S., Reynaud-Gaubert, M., Salaun, M., Sanchez, O., Trumbic, B., Berkani, K., Brillet, P.-Y., Campana, M., Chalabreysse, L., Chatté, G., Debieuvre, D., Ferretti, G., Fourrier, J.-M., Just, N., Kambouchner, M., Legrand, B., Le Guillou, F., Lhuillier, J.-P., Mehdaoui, A., Naccache, J.-M., Paganon, C., Rémy-Jardin, M., Si-Mohamed, S., and Terrioux, P.

Published
2022
Full Text
View/download PDF

7. [French practical guidelines for the diagnosis and management of IPF - 2021 update, full version]

Author

Cottin, V, Bonniaud, P, Cadranel, J, Crestani, B, Jouneau, S, Marchand-Adam, S, Nunes, H, Wémeau-Stervinou, L, Bergot, E, Blanchard, E, Borie, R, Bourdin, A, Chenivesse, C, Clément, Annick, Gomez-Quiroz, Luis E, Gondouin, A, Hirschi, S, Lebargy, F, Marquette, C.-H., Montani, D, Prévot, G, Quetant, S, Reynaud-Gaubert, M, Salaün, M, Sanchez, O, Trumbic, B, Berkani, K, Brillet, P.-Y., Campana, M, Chalabreysse, L, Chatté, G, Debieuvre, D, Ferretti, G, Fourrier, J.-M., Just, N, Kambouchner, M, Legrand, B, Le Guillou, F, Lhuillier, J.-P., Mehdaoui, A., Naccache, J.-M., Paganon, C, Rémy-Jardin, M, Si-Mohamed, S., Terrioux, P, Infections Virales et Pathologie Comparée - UMR 754 (IVPC), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre national de référence des maladies pulmonaires rares [Lyon] (CRMPM), Lipides - Nutrition - Cancer [Dijon - U1231] (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Agro Dijon, Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service de Pneumologie Soins Intensifs, Appareillage Respiratoire [CHU de Dijon], Centre Constitutif de Référence des Maladies Pulmonaires Rares [AP-HP Tenon], Centre national de référence des maladies pulmonaires rares [Lyon] (CRMPM)-Service de Pneumologie = Pneumologie - Oncologie Thoracique - Maladies Pulmonaires Rares [CHU Tenon], CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), École des Hautes Études en Santé Publique [EHESP] (EHESP), Hôpital Bretonneau, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Hôpital Avicenne [AP-HP], Institut Coeur Poumon [CHU Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), CHU Pessac, Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 (CIIL), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Centre National de la Recherche Scientifique (CNRS), Maladies génétiques d'expression pédiatrique [CHU Trousseau] (Inserm U933), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Trousseau [APHP], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Nouvel Hôpital Civil de Strasbourg, Centre Hospitalier Universitaire de Reims (CHU Reims), Hôpital Pasteur [Nice] (CHU), Institut de Recherche sur le Cancer et le Vieillissement (IRCAN), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), Hypertension arterielle pulmonaire physiopathologie et innovation thérapeutique, Centre Chirurgical Marie Lannelongue (CCML)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre Hospitalier Universitaire [Grenoble] (CHU), CHU Marseille, Laboratoire d'Informatique, de Traitement de l'Information et des Systèmes (LITIS), Université Le Havre Normandie (ULH), Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA), Centre d'Investigation Clinique [CHU Rouen] (CIC Rouen), Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Hypoxie et Poumon : pneumopathologies fibrosantes, modulations ventilatoires et circulatoires (H&P), UFR SMBH-Université Sorbonne Paris Nord, Centre Hospitalier Régional d'Orléans (CHRO), Hospices Civils de Lyon (HCL), Centre Hospitalier Emile Muller [Mulhouse] (CH E.Muller Mulhouse), Groupe Hospitalier de Territoire Haute Alsace (GHTHA), Evaluation des technologies de santé et des pratiques médicales - ULR 2694 (METRICS), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier Eure-Seine - Hôpital d'Evreux - Vernon (Evreux), Groupe Hospitalier Paris Saint-Joseph (hpsj), Services de Pneumologie, Exploration Fonctionnelle Respiratoire et Cardiologie (Hôpital Louis Pradel), Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé (CREATIS), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), and Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Biopsie, Biopsy, [SDV]Life Sciences [q-bio], Fibrose pulmonaire, Pneumopathie interstitielle commune, Interstitial lung disease, Common interstitial lung disease, Pneumopathie interstitielle diffuse, Pulmonary fibrosis
Abstract

National audience; BACKGROUND: Since the previous French guidelines were published in 2017, substantial additional knowledge about idiopathic pulmonary fibrosis has accumulated. METHODS: Under the auspices of the French-speaking Learned Society of Pulmonology and at the initiative of the coordinating reference center, practical guidelines for treatment of rare pulmonary diseases have been established. They were elaborated by groups of writers, reviewers and coordinators with the help of the OrphaLung network, as well as pulmonologists with varying practice modalities, radiologists, pathologists, a general practitioner, a head nurse, and a patients’ association. The method was developed according to rules entitled "Good clinical practice" in the overall framework of the "Guidelines for clinical practice" of the official French health authority (HAS), taking into account the results of an online vote using a Likert scale. RESULTS: After analysis of the literature, 54 recommendations were formulated, improved, and validated by the working groups. The recommendations covered a wide-ranging aspects of the disease and its treatment: epidemiology, diagnostic modalities, quality criteria and interpretation of chest CT, indication and modalities of lung biopsy, etiologic workup, approach to familial disease entailing indications and modalities of genetic testing, evaluation of possible functional impairments and prognosis, indications for and use of antifibrotic therapy, lung transplantation, symptom management, comorbidities and complications, treatment of chronic respiratory failure, diagnosis and management of acute exacerbations of fibrosis. CONCLUSION: These evidence-based guidelines are aimed at guiding the diagnosis and the management in clinical practice of idiopathic pulmonary fibrosis.

Published
2022

11. Sarcoidosis, inorganic dust exposure and content of bronchoalveolar lavage fluid: the MINASARC pilot study

Author

Catinon, M., Cavalin, C., Chemarin, C., Rio, S., Roux, E., Pecquet, M., Blanchet, A. -S, Vuillermoz, S., Pison, C., Arbib, F., Bonneterre, V., dominique Valeyre, Freynet, O., Mornex, J. -F, Pacheco, Y., Freymond, N., Thivolet, F., Kambouchner, M., Bernaudin, J. -F, Nathalizio, A., Pradat, P., Rosental, P. -A, and Vincent, M.

Subjects
Original Article: Clinical Research, bronchoalveolar lavage, sarcoidosis, dust exposure, respiratory tract diseases
Abstract

Inhalation of mineral dust was suggested to contribute to sarcoidosis. We compared the mineral exposome of 20 sarcoidosis and 20 matched healthy subjects. Bronchoalveolar lavage (BAL) samples were treated by digestion-filtration and analyzed by transmission electron microscopy. The chemical composition of inorganic particles was determined by energy-dispersive X-ray (EDX) spectroscopy. Dust exposure was also assessed by a specific questionnaire. Eight sarcoidosis patients and five healthy volunteers had a high dust load in their BAL. No significant difference was observed between the overall inorganic particle load of each group while a significant higher load for steel was observed in sarcoidosis patients (p=0.029). Moreover, the building activity sub-score was significantly higher in sarcoidosis patients (p=0.018). These results suggest that building work could be a risk factor for sarcoidosis which could be considered at least in some cases as a granulomatosis caused by airborne inorganic dust. The questionnaire should be validated in larger studies. (Sarcoidosis Vasc Diffuse Lung Dis 2018; 35: 327-332)

Published
2020

12. French practical guidelines for the diagnosis and management of IPF-2021 update, short version

Author

Cottin, V, Bonniaud, P., Cadranel, J., Crestani, B., Jouneau, S., Marchand-Adam, S., Nunes, H., Wemeau-Stervinou, L., Bergot, E., Blanchard, E., Borie, R., Bourdin, A., Chenivesse, C., Clement, A., Gomez, E., Gondouin, A., Hirschi, S., Lebargy, F., Marquette, C-H, Montani, D., Prevot, G., Quetant, S., Reynaud-Gaubert, M., Salaun, M., Sanchez, O., Trumbic, B., Berkani, K., Brillet, P-Y, Campana, M., Chalabreysse, L., Chatte, G., Debieuvre, D., Ferretti, G., Fourrier, J-M, Just, N., Kambouchner, M., Legrand, B., Le Guillou, F., Lhuillier, J-P, Mehdaoui, A., Naccache, J-M, Paganon, C., Remy-Jardin, M., Si-Mohamed, S., Terrioux, P., Infections Virales et Pathologie Comparée - UMR 754 (IVPC), École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Hôpital Louis Pradel [CHU - HCL], Hospices Civils de Lyon (HCL), RespiFIL, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Lipides - Nutrition - Cancer [Dijon - U1231] (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Agro Dijon, Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro), CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Groupe de recherche clinique Biomarqueurs Théranostiques des Cancers Bronchiques Non à Petites Cellules (GRC 4 - Theranoscan), Sorbonne Université (SU), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Pontchaillou [Rennes], Hôpital Bretonneau, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Hôpital Avicenne [AP-HP], Université Sorbonne Paris Nord, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut Coeur Poumon [CHU Lille], Service de pneumologie [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Hôpital Côte de Nacre [CHU Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Hôpital Arnaud de Villeneuve [CHRU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 (CIIL), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Centre National de la Recherche Scientifique (CNRS), Hôpital Albert Calmette, Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Trousseau [APHP], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Nouvel Hôpital Civil de Strasbourg, Hôpital Maison Blanche, Centre Hospitalier Universitaire de Reims (CHU Reims), Institut de Recherche sur le Cancer et le Vieillissement (IRCAN), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), FHU OncoAge - Pathologies liées à l’âge [CHU Nice] (OncoAge), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Pharmacologie Moléculaire et Cellulaire [UNIV Côte d'Azur] (UPMC)-Université Côte d'Azur (UCA), Hôpital Pasteur [Nice] (CHU), Hypertension pulmonaire : physiopathologie et innovation thérapeutique (HPPIT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Hôpital Bicêtre, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre Hospitalier Universitaire [Grenoble] (CHU), Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Hôpital Nord [CHU - APHM], Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), Service de pneumologie, oncologie thoracique et soins intensifs respiratoires [Rouen], Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Centre d'Investigation Clinique [CHU Rouen] (CIC Rouen), Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire d'Informatique, du Traitement de l'Information et des Systèmes (LITIS), Université Le Havre Normandie (ULH), Normandie Université (NU)-Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Hypoxie et Poumon : pneumopathologies fibrosantes, modulations ventilatoires et circulatoires (H&P), UFR SMBH-Université Sorbonne Paris Nord, CHU Orléans, Groupement Hospitalier Lyon-Est (GHE), Groupe hospitalier de la région de Mulhouse Sud-Alsace (GHRMSA), Centre Hospitalier Emile Muller [Mulhouse] (CH E.Muller Mulhouse), Groupe Hospitalier de Territoire Haute Alsace (GHTHA), Université Grenoble Alpes (UGA), Centre Hospitalier Victor Provo, CHU Lille, Evaluation des technologies de santé et des pratiques médicales - ULR 2694 (METRICS), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre d'Etudes et de Recherche en Informatique Médicale [Lille] (CERIM), Centre Hospitalier Eure-Seine - Hôpital d'Evreux - Vernon (Evreux), Centre hospitalier Saint-Joseph [Paris], Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé (CREATIS), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), and Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Biopsy, Interstitial lung disease, Common interstitial lung disease, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, Pulmonary fibrosis
Abstract

National audience; Background. - Since the previous French guidelines were published in 2017, substantial additional knowledge about idiopathic pulmonary fibrosis has accumulated. Methods. - Under the auspices of the French-speaking Learned Society of Pulmonology and at the initiative of the coordinating reference center, practical guidelines for treatment of rare pulmonary diseases have been established. They were elaborated by groups of writers, reviewers and coordinators with the help of the OrphaLung network, as well as pulmonologists with varying practice modalities, radiologists, pathologists, a general practitioner, a head nurse, and a patients' association. The method was developed according to rules entitled "Good clinical practice" in the overall framework of the "Guidelines for clinical practice" of the official French health authority (HAS), taking into account the results of an online vote using a Likert scale. Results. - After analysis of the literature, 54 recommendations were formulated, improved, and validated by the working groups. The recommendations covered a wide-ranging aspects of the disease and its treatment: epidemiology, diagnostic modalities, quality criteria and interpretation of chest CT, indication and modalities of lung biopsy, etiologic workup, approach to familial disease entailing indications and modalities of genetic testing, evaluation of possible functional impairments and prognosis, indications for and use of antifibrotic therapy, lung transplantation, symptom management, comorbidities and complications, treatment of chronic respiratory failure, diagnosis and management of acute exacerbations of fibrosis. Conclusion. - These evidence-based guidelines are aimed at guiding the diagnosis and the management in clinical practice of idiopathic pulmonary fibrosis. (C) 2022 SPLF. Published by Elsevier Masson SAS. All rights reserved.

Published
2022

16. Low grade marginal zone B cell lymphoma of the breast associated with localised amyloidosis and corpora amylacea in a woman with long standing primary Sjogren's syndrome. (Case Report)

Author

Kambouchner, M., Godmer, P., Guillevin, L., Raphael, M., Droz, D., and Martin, A.

Subjects
Lymphomas -- Case studies, Sjogren's syndrome -- Case studies, Breast cancer -- Case studies, Amyloidosis -- Case studies, Health
Abstract

Primary low grade marginal zone B cell lymphoma (MZL) of the breast and localised mammary amyloidosis are exceedingly rare entities. This report describes the case of a woman with long [...]

Published
2003

18. Sarcoïdose

Author

Valeyre, D., Nunes, H., Duperron, F., Soler, P., Kambouchner, M., and Brauner, M.

Published
2005
Full Text
View/download PDF

24. Présentation, survie et facteurs de survie de l’amylose respiratoire : une série multicentrique Française de 73 patients

Author

Rech, J.S., primary, Arnulf, B., additional, De Margerie Mellon, C., additional, Malphettes, M., additional, Vignon, M., additional, Lavergne, D., additional, Kambouchner, M., additional, Meignin, V., additional, Bergeron-Lafaurie, A., additional, Prevot, G., additional, Brillet, P.Y., additional, Martinod, E., additional, Valeyre, D., additional, Jaccard, A., additional, Nunes, H., additional, and Uzunhan, Y., additional

Published
2019
Full Text
View/download PDF

27. Analyse minéralogique par microscopie électronique et par Laser Induced Breakdown Spectroscopy (LIBS) chez deux patients atteints de sarcoïdose issus de l’étude MINASARC

Author

Catinon, M., primary, Busser, B., additional, Thivolet, F., additional, Kambouchner, M., additional, Bernaudin, J.F., additional, Freynet, O., additional, Valeyre, D., additional, Cavalin, C., additional, Rosental, P.A., additional, Sfarghiu, A.M., additional, Arbib, F., additional, Pison, C., additional, Bonneterre, V., additional, Motto-Ros, V., additional, and Vincent, M., additional

Published
2018
Full Text
View/download PDF

29. Analyses minéralogiques de lavages bronchiolo-alvéolaire (LBA) de sujets sains par détection automatique de particules – Intérêt de leur utilisation comme groupe-contrôle dans le cadre de la mise en évidence d’une exposition professionnelle et/ou environnementale

Author

Chemarin, C., primary, Catinon, M., additional, Cavalin, C., additional, Roux, E., additional, Rio, S., additional, Pecquet, M., additional, Blanchet, A.S., additional, Vuillermoz, S., additional, Pison, C., additional, Arbib, F., additional, Bonneterre, V., additional, Valeyre, D., additional, Freynet, O., additional, Mornex, J.F., additional, Freymond, N., additional, Pacheco, Y., additional, Thivolet, F., additional, Kambouchner, M., additional, Bernaudin, J.F., additional, Nathalizio, A., additional, Rosental, P.A., additional, and Vincent, M., additional

Published
2017
Full Text
View/download PDF

36. Aspects TDM rares de la sarcoïdose thoracique

Author

Maulat, Y., Brillet, Pierre Yve, Nunes, H., Valeyre, D., Kambouchner, M., Dumas, J.L., Brauner, M., Département Advanced Research And Techniques For Multidimensional Imaging Systems (ARTEMIS), Institut Mines-Télécom [Paris] (IMT)-Télécom SudParis (TSP), and Preteux, Francoise

Published
2004

39. Langerhans cells in Langerhans cell granulomatosis are not actively proliferating cells

Author

Brabencova, E., Tazi, A., Lorenzato, M., Marcel Bonay, Kambouchner, M., Emile, J. -F, Hance, A. J., and Soler, P.

Subjects
Adult, Male, Lung Neoplasms, Infant, DNA, DNA, Neoplasm, Adenocarcinoma, Middle Aged, Immunohistochemistry, Histiocytosis, Langerhans-Cell, Ki-67 Antigen, Child, Preschool, Langerhans Cells, Proliferating Cell Nuclear Antigen, Carcinoma, Squamous Cell, Mitotic Index, Nucleolus Organizer Region, Humans, Female, Child, Cell Division, Aged, Research Article
Abstract

Pulmonary Langerhans cell granulomatosis (LCG), also called histiocytosis X, is a disorder of unknown etiology characterized by the presence of destructive granulomas containing numerous Langerhans cells (LCs). The process may be localized or multifocal, and it remains unclear whether the same pathogenic mechanism is involved in all forms of the disease. It is often assumed that the massive accumulation of LCs at the sites of the lesions results from the abnormal proliferation of these cells, although it has been suggested that LCG in adults, at least in the lung, could be a reactive disorder initiated by activated LCs. Little is known, however, concerning the mechanisms responsible for the accumulation of large numbers of LCs in the course of the disease, and the relative contribution of recruitment and local proliferation of these cells remains to be established. To investigate this question, the proportion of replicating LCs was evaluated in biopsied granulomas from patients with localized or diffuse form of LCG by means of several histopathological techniques currently used in assessment of cell proliferation. The findings demonstrate that, except for proliferating cell nuclear antigen (PCNA), all parameters measured are low in all forms of the disease. They are similar to those of renewing epithelial cells and clearly less than those of neoplastic cells. These data strongly suggest that LCs in LCG granulomas are not a rapidly dividing cell population and that local LC replication makes only a minimal contribution to granuloma maintenance. Caution appears to be necessary in the use of PCNA as a marker of growth fraction.

Published
1998

40. Small airways diseases, excluding asthma and COPD: an overview

Author

Burgel, P.-R., primary, Bergeron, A., additional, de Blic, J., additional, Bonniaud, P., additional, Bourdin, A., additional, Chanez, P., additional, Chinet, T., additional, Dalphin, J.-C., additional, Devillier, P., additional, Deschildre, A., additional, Didier, A., additional, Kambouchner, M., additional, Knoop, C., additional, Laurent, F., additional, Nunes, H., additional, Perez, T., additional, Roche, N., additional, Tillie-Leblond, I., additional, and Dusser, D., additional

Published
2013
Full Text
View/download PDF

43. La fréquence des mutations de BRAF est élevée dans les histiocytoses de Langerhans et d’Erdheim-Chester, mais nulle dans les autres histiocytoses

Author

Charlotte, F., primary, Haroche, J., additional, Arnaud, L., additional, Von Deimling, A., additional, Hélias-Rodzewicz, Z., additional, Hervier, B., additional, Cohen, F., additional, Launay, D., additional, Lesot, A., additional, Mokhtari, K., additional, Canioni, D., additional, Galmiche, L., additional, Rose, C., additional, Schmalzing, M., additional, Croockewit, S., additional, Kambouchner, M., additional, Copin, M.-C., additional, Fraitag, S., additional, Sahm, F., additional, Brousse, N., additional, Amoura, Z., additional, Donadieu, J., additional, and Emile, J.-F., additional

Published
2012
Full Text
View/download PDF

50. A French National Prospective Cohort of Patients with Idiopathic Pulmonary Fibrosis (IPF): Demographic Characteristics.

Author

Nunes, H, primary, Carton, Z, additional, Cottin, V, additional, Israel-Biet, D, additional, Brauner, M, additional, Kambouchner, M, additional, Cadranel, J, additional, Prevot, G, additional, Juvin, K, additional, Wislez, M, additional, Crestani, B, additional, Maitre, B, additional, Marchand-Adam, S, additional, Wallaert, B, additional, Borie, R, additional, Feuillet, S, additional, Sanchez, O, additional, Chevret, S, additional, Cordier, J, additional, and Valeyre, D, additional

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results